Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

GenSight Biologics S.A. (Euronext: SIGHT)

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage, a marketing authorization application is currently under review by the EMA for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. *


Period Start 2013-04-08 existent
Products Industry ophthalmic
  Industry 2 gene therapy
Persons Person Gilly, Bernard (GenSight Biologics 201304 CEO + Co-founder before Fovea + Sofinnova Partners + Transgene)
  Person 2 Tortet, Ivan (GenSight Biologics 202402 CFO)
Region Region Paris
  Country France
  Street 74 rue du Faubourg Saint-Antoine
  City 75012 Paris
  Tel +33-1-7621-7220
    Address record changed: 2020-12-02
Basic data Employees n. a.
  Currency EUR
  Annual sales 3,000,665 (income, operation (2016) 2016-12-31)
  Profit -22,018,686 (2016-12-31)
  Cash 63,600,000 (2017-06-30)
    * Document for »About Section«: GenSight Biologics S.A.. (12/22/23). "Press Release: GenSight Biologics Appoints Laurence Rodriguez as Chief Executive Officer". Paris.
Record changed: 2024-06-07


Picture Berlin Partner Top News Captain T Cell Therapies 650x200px

More documents for GenSight Biologics S.A. (Euronext: SIGHT)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px

» top